Research
FORUM TRANSCRIPT

Illumina Sequencing Update – Long-term Diversification Outlook – 17 November 2021

  • Public Equity
  • Healthcare
  • North America
PREMIUM

Specialist

Former product manager at Illumina Inc.

Agenda

  • Recent developments and regulatory scrutiny around Illumina’s (NASDAQ: ILMN) acquisition of Grail, including outlook
  • Sequencing industries competitive landscape – PacBio (NASDAQ: PACB) vs Oxford Nanopore (LON: ONT) vs Illumina (NASDAQ: ILMN) vs BGI Genomics (SHE: 300676)
  • Illumina's expansion into clinical genomics and possibility of expanding in proteomics via M&A
  • 2022 outlook and growth expectations

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo